KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) EBITDA (2016 - 2025)

Evolent Health (EVH) has 11 years of EBITDA data on record, last reported at -$429.4 million in Q4 2025.

  • For Q4 2025, EBITDA fell 1285.05% year-over-year to -$429.4 million; the TTM value through Dec 2025 reached -$580.3 million, down 517.64%, while the annual FY2025 figure was -$580.3 million, 517.64% down from the prior year.
  • EBITDA reached -$429.4 million in Q4 2025 per EVH's latest filing, down from -$27.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.9 million in Q3 2022 and bottomed at -$429.4 million in Q4 2025.
  • Average EBITDA over 5 years is -$43.7 million, with a median of -$25.7 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 114.28% in 2022, then crashed 1891.89% in 2023.
  • A 5-year view of EBITDA shows it stood at -$5.6 million in 2021, then tumbled by 103.38% to -$11.5 million in 2022, then crashed by 260.42% to -$41.4 million in 2023, then grew by 25.09% to -$31.0 million in 2024, then crashed by 1285.05% to -$429.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$429.4 million in Q4 2025, -$27.6 million in Q3 2025, and -$51.1 million in Q2 2025.